Literature DB >> 24127282

The FOXE1 locus is a major genetic determinant for familial nonmedullary thyroid carcinoma.

Elena Bonora1, Cosmeri Rizzato, Chiara Diquigiovanni, Tiphaine Oudot-Mellakh, Daniele Campa, Manuela Vargiolu, Mickaël Guedj, James D McKay, Giovanni Romeo, Federico Canzian, Fabienne Lesueur.   

Abstract

Thyroid cancer is the most common endocrine malignancy and nonmedullary thyroid carcinoma (NMTC) represents 90% of all cases. NMTC risk in first-degree relatives of affected cases is elevated fivefold to ninefold. Familial NMTC (FNMTC) accounts for about 3-7% of all thyroid tumors and is a more aggressive clinical entity than its sporadic counterparts. Linkage analysis on high-risk families performed a decade ago mapped several susceptibility loci, but did not lead to the identification of high-penetrance causal germline mutations. More recently, a genome-wide association study (GWAS) identified common single nucleotide polymorphisms (SNPs) affecting the risk of sporadic NMTC. We sought to verify if the newly identified genetic risk factors for NMTC are relevant for FNMTC as well. We genotyped 23 SNPs at 11 candidate loci in 672 subjects belonging to 133 pedigrees with at least two NMTC cases. Statistical analysis was performed using family-based association tests, modified quasi-likelihood score and logistic-normal models. SNPs at 9q22.33 near FOXE1 showed convincing evidence of association with NMTC risk in these high-risk families. The other tested loci resulted negative. These findings confirm the importance of the SNPs identified by recent GWAS on sporadic NMTC on FNMTC as well. However, the proposed FOXE1 causal variants do not show the strongest association signal. Moreover, mutation screening of the FOXE1 coding sequence in the FNMTC cases did not identify rarer causal variants, suggesting that other yet unidentified variants at this locus are involved in FNMTC etiology.
© 2013 UICC.

Entities:  

Keywords:  genetic association study; genetic predisposition; nonmedullary thyroid carcinoma; single nucleotide polymorphisms

Mesh:

Substances:

Year:  2013        PMID: 24127282     DOI: 10.1002/ijc.28543

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  19 in total

1.  Common genetic variant on 14q13.3 contributes to thyroid cancer susceptibility: evidence based on 12 studies.

Authors:  JiaoJiao Zheng; Chen Li; Cong Wang; Zhilong Ai
Journal:  Mol Genet Genomics       Date:  2015-01-01       Impact factor: 3.291

2.  Common genetic variants on FOXE1 contributes to thyroid cancer susceptibility: evidence based on 16 studies.

Authors:  Yixin Zhuang; Weixin Wu; Han Liu; Weixin Shen
Journal:  Tumour Biol       Date:  2014-04-18

3.  Selected single-nucleotide polymorphisms in FOXE1, SERPINA5, FTO, EVPL, TICAM1 and SCARB1 are associated with papillary and follicular thyroid cancer risk: replication study in a German population.

Authors:  Alice J Sigurdson; Alina V Brenner; James A Roach; Lilia Goudeva; Jörg A Müller; Kai Nerlich; Christoph Reiners; Robert Schwab; Liliane Pfeiffer; Melanie Waldenberger; Melissa Braganza; Li Xu; Erich M Sturgis; Meredith Yeager; Stephen J Chanock; Ruth M Pfeiffer; Michael Abend; Matthias Port
Journal:  Carcinogenesis       Date:  2016-04-28       Impact factor: 4.944

4.  Association between FOXP3 gene polymorphisms and risk of differentiated thyroid cancer in Chinese Han population.

Authors:  Weichao Jiang; Lei Zheng; Lijuan Xu; Yang Zhang; Xingxin Liu; Lihua Hu; Xiaobei Wang
Journal:  J Clin Lab Anal       Date:  2016-11-28       Impact factor: 2.352

Review 5.  Genetic predisposition for nonmedullary thyroid cancer.

Authors:  Rebecca Nagy; Matthew D Ringel
Journal:  Horm Cancer       Date:  2014-10-22       Impact factor: 3.869

6.  A single nucleotide polymorphism associated with isolated cleft lip and palate, thyroid cancer and hypothyroidism alters the activity of an oral epithelium and thyroid enhancer near FOXE1.

Authors:  Andrew C Lidral; Huan Liu; Steven A Bullard; Greg Bonde; Junichiro Machida; Axel Visel; Lina M Moreno Uribe; Xiao Li; Brad Amendt; Robert A Cornell
Journal:  Hum Mol Genet       Date:  2015-02-04       Impact factor: 6.150

Review 7.  Overview of the 2022 WHO Classification of Familial Endocrine Tumor Syndromes.

Authors:  Vania Nosé; Anthony Gill; José Manuel Cameselle Teijeiro; Aurel Perren; Lori Erickson
Journal:  Endocr Pathol       Date:  2022-03-13       Impact factor: 3.943

8.  Multiple functional variants in long-range enhancer elements contribute to the risk of SNP rs965513 in thyroid cancer.

Authors:  Huiling He; Wei Li; Sandya Liyanarachchi; Mukund Srinivas; Yanqiang Wang; Keiko Akagi; Yao Wang; Dayong Wu; Qianben Wang; Victor Jin; David E Symer; Rulong Shen; John Phay; Rebecca Nagy; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

9.  Genetic predisposition to papillary thyroid carcinoma: involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2.

Authors:  Huiling He; Wei Li; Sandya Liyanarachchi; Jaroslaw Jendrzejewski; Mukund Srinivas; Ramana V Davuluri; Rebecca Nagy; Albert de la Chapelle
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 10.  Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).

Authors:  Chiara Diquigiovanni; Elena Bonora
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.